TMDX241220C65000
- 12.18
- 0.000.00%
TransMedics Newsroom
TransMedics' Positive Trajectory: Buy Rating Reinforced by Growth in Heart and Lung Transplants
Needham Downgrades TransMedics(TMDX.US) to Hold Rating
Needham Downgrades TransMedics Gr to Hold, Maintains Price Target to $109
Oppenheimer Maintains TransMedics(TMDX.US) With Buy Rating, Cuts Target Price to $125
TransMedics Group (TMDX) Gets a Buy From Oppenheimer
TransMedics Group Is Maintained at Buy by Canaccord Genuity
TransMedics Group Price Target Cut to $104.00/Share From $109.00 by Canaccord Genuity
CCORF Maintains TransMedics(TMDX.US) With Buy Rating, Cuts Target Price to $104
Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Cuts Target Price to $110
TransMedics Gr Analyst Ratings
TD Cowen Maintains TransMedics(TMDX.US) With Buy Rating, Cuts Target Price to $120
Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $180
Piper Sandler Keeps Their Buy Rating on TransMedics Group (TMDX)
Morgan Stanley Maintains TransMedics(TMDX.US) With Hold Rating, Cuts Target Price to $87
TD Cowen Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $175
TransMedics Group Price Target Cut to $125.00/Share From $200.00 by Oppenheimer
Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $180
A Quick Look at Today's Ratings for TransMedics(TMDX.US), With a Forecast Between $150 to $180
TransMedics Group Is Maintained at Outperform by Baird
TransMedics Gr Analyst Ratings